Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.

摘要: Neurologic events during left ventricular assist device (LVAD) support are associated with significant morbidity and death. To evaluate this problem, we analyzed neurocognitive function the frequency incidence of neurologic in 21 consecutive patients who were undergoing long-term HeartMate® XVE LVAD (Thoratec Corporation; Pleasanton, Calif). The mean duration was 531 days (range, 55–1,309 d); cumulative time 11,188 (30.7 yr). No received anticoagulant therapy, most aspirin. None experienced strokes or transient ischemic attacks. Twenty discharged from hospital; 2 later readmitted because changes status (metabolic encephalopathy) that ultimately resolved. function, as measured by National Institutes Health Stroke Scale (NIHSS) Modified Rankin Score (MRS), abnormal before implantation but normal 6 12 months after (mean NIHSS, 23.6 vs 0 after; MRS, 0.68 0.18 after). Neurocognitive evaluated Boston Naming Test, Trail Making Test part B, Block Design also improved support. Together, these findings indicate few occur HeartMate absence anticoagulation therapy. They suggest modifications made to since REMATCH trial have resulted fewer complications, better patient selection supportive care outcomes.